# Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

> clinical trial · VERIFIED · 2026-07-08

Status: COMPLETED · Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Condition: Pulmonary TB

- Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT05221502

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.